Ignite Creation Date:
2024-05-05 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00486252
Status:
COMPLETED
Last Update Posted:
2021-03-01
First Post:
2007-06-12
Brief Title:
Non Interventional Study in Patients With Open Angle Glaucoma andor Ocular Hypertension Treated With XALATAN
Sponsor:
Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization:
Pfizer
Study Overview
Official Title:
Non Interventional Study in Patients With Open Angle Glaucoma andor Ocular Hypertension Treated With XALATAN Latanoprost as First-Line Monotherapy and as Second-Line Monotherapy After Beta-Blockers Therapy Failure
Status:
COMPLETED
Status Verified Date:
2009-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective is to evaluate the Intraocular pressure reducing effect of Xalatan over 3 months The secondary objective is to study the other efficacy parameters during treatment for 3 months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None